Jefferies Group LLC reaffirmed their buy rating on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) in a research report report published on Tuesday. Jefferies Group LLC currently has a $40.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on the stock. J P Morgan Chase & Co assumed coverage on shares of La Jolla Pharmaceutical in a research note on Wednesday, August 30th. They set an overweight rating and a $36.00 price objective for the company. BidaskClub raised shares of La Jolla Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, August 9th. Chardan Capital reaffirmed a buy rating and set a $85.00 price objective on shares of La Jolla Pharmaceutical in a research note on Tuesday, August 8th. Finally, Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a buy rating to a hold rating in a research report on Tuesday, July 18th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. La Jolla Pharmaceutical has an average rating of Buy and a consensus price target of $54.60.

Shares of La Jolla Pharmaceutical (NASDAQ LJPC) traded up 3.43% on Tuesday, reaching $35.91. 278,435 shares of the company’s stock traded hands. The stock’s 50-day moving average price is $33.08 and its 200-day moving average price is $30.78. The stock’s market capitalization is $794.44 million. La Jolla Pharmaceutical has a 52 week low of $14.63 and a 52 week high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.12) by ($0.09). During the same quarter in the prior year, the business earned ($0.90) EPS. Equities analysts predict that La Jolla Pharmaceutical will post ($4.99) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/la-jolla-pharmaceuticals-ljpc-buy-rating-reiterated-at-jefferies-group-llc/1615567.html.

A number of institutional investors and hedge funds have recently bought and sold shares of LJPC. Legal & General Group Plc increased its position in La Jolla Pharmaceutical by 11.6% during the 2nd quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 462 shares in the last quarter. SG Americas Securities LLC acquired a new stake in La Jolla Pharmaceutical during the 1st quarter worth approximately $195,000. Voya Investment Management LLC acquired a new stake in La Jolla Pharmaceutical during the 2nd quarter worth approximately $243,000. American International Group Inc. increased its position in La Jolla Pharmaceutical by 7.1% during the 1st quarter. American International Group Inc. now owns 8,571 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 568 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new stake in La Jolla Pharmaceutical during the 1st quarter worth approximately $271,000.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.